Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • CG-806 for B-cell Tumors
    • CG-806 for Myeloid Tumors
    • APTO-253
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • CG-806 for CLL & NHL
    • CG-806 for AML
    • APTO-253 for AML & MDS
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Press Releases

News

News

  • Press Releases
  • Presentations
  • Events

Aptose to Release Second Quarter Ended June 30, 2020 Financial ResultsĀ and Hold Conference Call on August 4, 2020

Jul 21, 2020 4:01pm EDT

Aptose Announces Pricing of Public Offering of Common Shares

Jul 15, 2020 10:49pm EDT

Aptose Announces Proposed Public Offering of Common Shares

Jul 15, 2020 4:01pm EDT

Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia

Jun 29, 2020 7:01am EDT

Aptose Presents Early Phase 1a/b CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

Jun 12, 2020 7:00am EDT

Aptose Biosciences Announces Results of Annual Meeting of Shareholders

Jun 02, 2020 5:49pm EDT

Aptose to Present Early CG-806 Clinical Findings at the 25th Congress of the European Hematology Association

May 14, 2020 9:00am EDT

Aptose to Present at 2020 RBC Capital Markets Global Healthcare Virtual Conference

May 07, 2020 7:30am EDT

Aptose Biosciences Establishes New At-The-Market Facility

May 05, 2020 4:17pm EDT

Aptose Reports Results for the First Quarter 2020

May 05, 2020 4:00pm EDT
RSS
  • Prev
    • 1
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • ...20
    Next
    © 2021 Aptose Biosciences Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap